News Releases

News & Events

News Releases

Synteract Expands Participation in Industry Meetings in US and Europe

European regional industry meetings and ASCO annual meeting in the U.S. offer multiple opportunities for biopharma companies to meet the merged teams

SAN DIEGO – May 21, 2013 – Synteract, a full-service global contract research organization (CRO), will attend two regional European meetings in May, Italian National Pharma Forum and FlandersBio Meeting. The CRO will also be at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Ill. By participating in an expanded schedule of global industry events due to the enhanced scope and scale of the company’s multinational capabilities, Synteract is showcasing its expanded geographic footprint and expertise following its recent merger.

Synteract will exhibit at booth #9 at the ninth annual FlandersBio Meeting in Ghent, Belgium on May 30, 2013, a life science convention called Knowledge for Growth. This year the conference will cover topics including research and funding, financial markets, international business and creativity. More than 1,000 industry professionals are expected. Attendees who visit the booth will have the opportunity to meet Erik Gobbers, lead generation specialist; Rafaël Hoebrechts, international vendor manager and Veerle Bultinck, senior training coordinator.

The sixth Italian National Pharma Forum will take place in Sardinia, Italy from May 29-31, 2013. This year the meeting will address pressing pharmaceutical issues and will feature discussions to encourage the exchange of ideas from participants. The event is highly attended by industry professionals who are interested in the latest research innovations in pharmacology. Managing Director of Synteract’s Italian operations, Dr. Luigi Godi, will be attending and available to discuss our clinical development expertise in Europe.

Synteract will be at the ASCO Annual Meeting from May 31 to June 6, 2013 in Chicago. The theme of the meeting “Building Bridges to Conquer Cancer” will bring together more than 25,000 oncology professionals from a wide range of specialties. Synteract’s new Chief Medical Officer Dr. Richard Paul will be available to discuss the company’s extensive oncology clinical development experience.

To set up an appointment, contact Matt Smith, SVP sales and marketing at +1 760-268-8200.

About Synteract (www.synteract.com)
Synteract is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. With its “Shared Work – Shared Vision” philosophy Synteract provides customized Phase I through IV services collaboratively and cost effectively ensuring on-time delivery of quality data so clients get to decision points faster. Operating in 16 countries, Synteract delivers trials internationally, offering expertise across multiple therapeutic areas including notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications.

###

MEDIA CONTACT:
Antonia Genov
antonia@clearpointagency.com
760-230-2424

x

Contact Synteract

Tell us how to stay in touch with you:

*Required